Why the study?
Does ACE-inhibitory peptide LAP reduce systolic blood pressure in spontaneously hypertensive rats?
Does ACE-inhibitory peptide LAP reduce systolic blood pressure in spontaneously hypertensive rats?
The ACE-inhibitory peptide LAP demonstrates a significant and prolonged antihypertensive effect in a spontaneously hypertensive rat model.
OBJECTIVE: To study the antihypertensive effects of the angiotensin-converting enzyme (ACE)-inhibitory peptide LAP on blood pressure in spontaneously hypertensive rats (SHRs). METHODS: A cohort of 12-week-old SHRs was randomly divided into 2 distinct groups, and ACE-inhibitory peptide LAP (experimental group) or physiological saline (controls) were administered. Caudal arterial blood pressure was then measured at specific time points (0, 4, 8 and 12 weeks). RESULTS: Systolic blood pressure of the SHRs showed a significant decrease after intraperitoneal injection with the ACE-inhibitory peptide LAP. Moreover, this depressurization effect lasted for over 1 month. CONCLUSION: Systolic blood pressure of SHRs could effectively be depressed in the long term by antihypertensive activity mediated by the ACE-inhibitory peptide LAP.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: